Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirk R Schultz

Showing results (151-160 of 217) with videos related to

Pageof 22
Sort By:
The Journal of Allergy and Clinical Immunology|December 17, 2013
Combined immunodeficiency associated with homozygous MALT1 mutationsMargaret L McKinnon, Jacob Rozmus, Shan-Yu Fung, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 8, 2016
Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group StudyStephen Couban, Mahmoud Aljurf, Sylvie Lachance, et al.
Blood|March 25, 2004
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcomeCorey S Cutler, Stephanie J Lee, Peter Greenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2020
Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic LeukemiaKimberly P Dunsmore, Stuart S Winter, Meenakshi Devidas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 4, 2015
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group ReportPaul A Carpenter, Carrie L Kitko, Sharon Elad, et al.
Haematologica|September 23, 2017
CD56<sup>bright</sup> natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-<i>versus</i>-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study resultsAmina Kariminia, Sabine Ivison, Bernard Ng, et al.
Bone Marrow Transplantation|February 21, 2024
Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHDLev Gorfinkel, Sharmila Raghunandan, Benjamin Watkins, et al.
Transplantation and Cellular Therapy|April 7, 2024
The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated ToxicitiesTakuto Takahashi, Benjamin Watkins, Brandi Bratrude, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 30, 2016
Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415]Stephen Couban, Mahmoud Aljurf, Sylvie Lachance, et al.
Blood|June 15, 2023
Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse eventsTakuto Takahashi, Mahmoud Al-Kofahi, Mutaz Jaber, et al.
Pageof 22

Showing results (151-160 of 217) with videos related to

Sort By:
Pageof 22
The Journal of Allergy and Clinical Immunology|December 17, 2013
Combined immunodeficiency associated with homozygous MALT1 mutationsMargaret L McKinnon, Jacob Rozmus, Shan-Yu Fung, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 8, 2016
Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group StudyStephen Couban, Mahmoud Aljurf, Sylvie Lachance, et al.
Blood|March 25, 2004
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcomeCorey S Cutler, Stephanie J Lee, Peter Greenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2020
Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic LeukemiaKimberly P Dunsmore, Stuart S Winter, Meenakshi Devidas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 4, 2015
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group ReportPaul A Carpenter, Carrie L Kitko, Sharon Elad, et al.
Haematologica|September 23, 2017
CD56<sup>bright</sup> natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-<i>versus</i>-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study resultsAmina Kariminia, Sabine Ivison, Bernard Ng, et al.
Bone Marrow Transplantation|February 21, 2024
Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHDLev Gorfinkel, Sharmila Raghunandan, Benjamin Watkins, et al.
Transplantation and Cellular Therapy|April 7, 2024
The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated ToxicitiesTakuto Takahashi, Benjamin Watkins, Brandi Bratrude, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 30, 2016
Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415]Stephen Couban, Mahmoud Aljurf, Sylvie Lachance, et al.
Blood|June 15, 2023
Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse eventsTakuto Takahashi, Mahmoud Al-Kofahi, Mutaz Jaber, et al.
Pageof 22